HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hisayoshi Fujiwara Selected Research

2,5-dihydroxybenzoic acid (gentisic acid)

7/2009Acarbose reduces myocardial infarct size by preventing postprandial hyperglycemia and hydroxyl radical production and opening mitochondrial KATP channels in rabbits.
12/2007In vivo hepatocyte growth factor gene transfer reduces myocardial ischemia-reperfusion injury through its multiple actions.
6/2003Quinaprilat reduces myocardial infarct size involving nitric oxide production and mitochondrial KATP channel in rabbits.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hisayoshi Fujiwara Research Topics

Disease

40Myocardial Infarction
01/2018 - 10/2002
31Heart Failure
03/2022 - 08/2004
31Infarction (Infarctions)
01/2018 - 04/2002
21Fibrosis (Cirrhosis)
01/2016 - 10/2004
19Ischemia
04/2011 - 01/2002
11Cardiomyopathies (Cardiomyopathy)
01/2019 - 08/2004
11Coronary Artery Disease (Coronary Atherosclerosis)
01/2018 - 01/2004
8Hypertrophy
03/2012 - 10/2004
7Thrombosis (Thrombus)
06/2015 - 05/2002
7Coronary Occlusion
09/2011 - 08/2002
6Cicatrix (Scar)
03/2009 - 06/2004
5Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
01/2020 - 02/2003
5Pathologic Constriction (Stenosis)
12/2015 - 07/2003
5Myocardial Ischemia (Ischemic Heart Diseases)
06/2015 - 04/2002
5Stroke (Strokes)
01/2015 - 12/2003
5Diabetes Mellitus
01/2012 - 05/2005
5Reperfusion Injury
09/2011 - 04/2002
5Hypertension (High Blood Pressure)
04/2011 - 04/2005
5Ventricular Remodeling
10/2007 - 05/2003
5Neoplasms (Cancer)
09/2006 - 02/2004
4Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
01/2014 - 02/2006
4Starvation
12/2012 - 05/2009
4Hemorrhage
06/2012 - 09/2011
4Chronic Obstructive Pulmonary Disease (COPD)
06/2012 - 05/2005
4Inflammation (Inflammations)
03/2012 - 09/2006
4Cardiovascular Diseases (Cardiovascular Disease)
01/2012 - 12/2007
4Essential Hypertension
11/2011 - 02/2006
4Diabetic Nephropathies (Diabetic Nephropathy)
11/2008 - 08/2005
3Heart Diseases (Heart Disease)
09/2019 - 02/2003
3Acute Coronary Syndrome
01/2018 - 10/2008
3Hypoxia (Hypoxemia)
07/2015 - 08/2010
3Cardiotoxicity
12/2012 - 03/2007
3Left Ventricular Dysfunction
03/2012 - 01/2004
3Emphysema
01/2012 - 10/2006
3Pneumonia (Pneumonitis)
01/2012 - 01/2007
3Cardiomegaly (Heart Hypertrophy)
07/2011 - 02/2003
3Peripheral Arterial Disease
04/2011 - 09/2006
3Necrosis
06/2009 - 10/2008
3Atrophy
02/2008 - 01/2006

Drug/Important Bio-Agent (IBA)

13Adenosine Triphosphate (ATP)IBA
12/2012 - 01/2002
13Granulocyte Colony-Stimulating Factor (G-CSF)IBA
04/2011 - 01/2003
10Doxorubicin (Adriamycin)FDA LinkGeneric
01/2019 - 01/2006
9LipidsIBA
01/2016 - 05/2002
8ErythropoietinFDA Link
04/2013 - 01/2006
8Hydroxyl RadicalIBA
07/2009 - 06/2003
7Indicators and Reagents (Reagents)IBA
01/2018 - 06/2003
7Proteins (Proteins, Gene)FDA Link
05/2014 - 09/2002
6Biomarkers (Surrogate Marker)IBA
06/2015 - 11/2006
6Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
05/2014 - 05/2003
5Amino AcidsFDA Link
09/2019 - 05/2009
5Pharmaceutical PreparationsIBA
01/2019 - 03/2007
5Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2018 - 08/2004
5TroponinIBA
06/2015 - 07/2007
5Green Fluorescent ProteinsIBA
12/2012 - 02/2004
5KATP ChannelsIBA
07/2009 - 10/2002
5CytokinesIBA
03/2009 - 03/2004
5Nitric Oxide (Nitrogen Monoxide)FDA Link
02/2008 - 06/2003
4Troponin T (Troponin T1)IBA
03/2022 - 10/2009
4Sirolimus (Rapamycin)FDA Link
04/2014 - 10/2008
4Cathepsin DIBA
12/2012 - 07/2006
4Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA
12/2012 - 05/2009
4Natriuretic PeptidesIBA
05/2012 - 09/2004
4Troponin IIBA
01/2012 - 01/2006
4Antihypertensive Agents (Antihypertensives)IBA
04/2011 - 02/2006
4Nitric Oxide Synthase (NO Synthase)IBA
06/2010 - 06/2003
4Fas Ligand Protein (Fas Ligand)IBA
02/2010 - 09/2004
4Coloring Agents (Dyes)IBA
05/2009 - 06/2003
4mitochondrial K(ATP) channelIBA
05/2009 - 01/2004
4Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
02/2008 - 06/2003
4Nicorandil (SG 75)IBA
11/2007 - 07/2003
4Protein Kinase CIBA
10/2007 - 10/2002
4NG-Nitroarginine Methyl Ester (L-NAME)IBA
04/2007 - 06/2003
45-hydroxydecanoic acidIBA
04/2007 - 10/2002
3DNA (Deoxyribonucleic Acid)IBA
01/2020 - 07/2005
3Therapeutic UsesIBA
05/2014 - 03/2004
3Angiotensin Receptor AntagonistsIBA
01/2014 - 04/2007
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2013 - 12/2009
3AlbuminsIBA
03/2013 - 10/2007
3human NPPA protein (carperitide)IBA
05/2012 - 05/2007
3Pancreatic Elastase (Elastase)IBA
01/2012 - 10/2006
3Superoxides (Superoxide)IBA
01/2012 - 04/2007
3Brain Natriuretic Peptide (Natrecor)FDA Link
01/2012 - 08/2004
3miglitol (Glyset)FDA Link
09/2011 - 07/2004
3Hypoglycemic Agents (Hypoglycemics)IBA
09/2011 - 05/2009
3candesartanIBA
04/2011 - 02/2008
3HydrogelsIBA
04/2011 - 09/2008
3GelatinIBA
04/2011 - 09/2008
3UbiquitinIBA
10/2009 - 07/2006
3Autophagy-Related ProteinsIBA
10/2009 - 07/2006
32,5-dihydroxybenzoic acid (gentisic acid)IBA
07/2009 - 06/2003
3Evans Blue (Blue, Evans)FDA Link
05/2009 - 06/2003
3Glucose (Dextrose)FDA LinkGeneric
01/2009 - 10/2008
3Biological ProductsIBA
09/2007 - 07/2005
3ChloridesIBA
04/2007 - 06/2003

Therapy/Procedure

24Therapeutics
01/2018 - 02/2004
9Percutaneous Coronary Intervention
01/2018 - 01/2004
6Stents
01/2015 - 01/2008
6Ligation
05/2014 - 02/2003
3Drug Therapy (Chemotherapy)
01/2019 - 01/2003
3Acupuncture Therapy
06/2012 - 05/2005